Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(100.0%)
1Total
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05648396Active Not Recruiting

Japan FFRangio Clinical Outcomes Study

Role: collaborator

NCT03351400Phase 1Unknown

Japanese OMI Treatment With Kit-positive Cells for Enhanced Regeneration

Role: lead

NCT03051191Completed

Pathogenic Mechanisms of Cancer and Cardiovascular Diseases

Role: lead

NCT04198896Completed

The Sakakibara Health Integrative Profile of Atherosclerotic-Carcinogenesis Hypothesis (SHIP-AC)

Role: lead

NCT03005834Completed

The Sakakibara Health Integrative Profile Cohort Study

Role: lead

All 5 trials loaded